StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Next report date, year-over-year trend, and recent quarter history.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $63.97 | $63.70 | -0.42% | 0.0M |
| 05-15 | $63.24 | $63.34 | +0.16% | 0.0M |
| 05-18 | $62.84 | $64.00 | +1.85% | 0.0M |
| 05-19 | $63.97 | $64.00 | +0.05% | 0.0M |
| 05-20 | $63.47 | $64.17 | +1.10% | 0.0M |
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows UTMD's percentile within the scored universe — observational ranking, not a recommendation.
No sell-side coverage available for UTMD yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Annual 2025 2025-09-30 | Annual 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $8.72M | $38.52M | $9.81M | $9.95M |
Operating Income | $2.56M | $11.40M | $8.96M | $6.35M |
Net Income | $2.60M | $11.29M | $2.63M | $3.05M |
EPS (Diluted) | $0.82 | $3.48 | $0.82 | $0.94 |
Total Assets | $124.38M | $122.54M | $121.97M | $120.80M |
Total Liabilities | $4.01M | $3.27M | $3.72M | $3.27M |
Cash & Equivalents | $87.41M | $85.76M | $84.27M | $82.18M |
Free Cash Flow OCF − CapEx | $2.98M | $14.32M | $10.95M | $7.10M |
Shares Outstanding | 3.18M | 3.19M | 3.20M | 3.22M |